See more : ManifestSeven Holdings Corporation (MSVN.CN) Income Statement Analysis – Financial Results
Complete financial analysis of Histogen Inc. (HSTO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Histogen Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Rogers Communications Inc. (RCI) Income Statement Analysis – Financial Results
- Echo Trading Co., Ltd. (7427.T) Income Statement Analysis – Financial Results
- The AES Corporation (AES.DE) Income Statement Analysis – Financial Results
- Tower One Wireless Corp. (TO.CN) Income Statement Analysis – Financial Results
- Fuji Oil Holdings Inc. (FJLLF) Income Statement Analysis – Financial Results
Histogen Inc. (HSTO)
About Histogen Inc.
Histogen Inc., a clinical-stage therapeutics company, focuses on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products. It offers HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; HST-004, a cell conditioned media solution to treat spinal disc repair; and Emricasan, an orally active pan-caspase inhibitor for the treatment of COVID-19. The company's preclinical product candidates include CTS-2090 and CTS-2096, which are selective caspase-1 inhibitors targeting inflammasome activation, as well as intervenes in a various inflammation mediated disease. Histogen Inc. was founded in 2007 and is headquartered in San Diego, California.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.77M | 919.00K | 2.06M | 11.30M | 33.59M | 35.38M | 799.05K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 220.00K | 968.00K | 2.22M | 0.00 | -4.00 | -4.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 3.77M | 699.00K | 1.09M | 9.09M | 33.59M | 35.38M | 799.05K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 100.00% | 76.06% | 52.99% | 80.41% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 5.02M | 8.47M | 6.22M | 4.10M | 41.37M | 43.22M | 20.29M | 16.30M | 14.91M | 6.95M |
| General & Administrative | 9.39M | 7.80M | 6.59M | 6.21M | 10.50M | 9.71M | 10.34M | 7.83M | 7.38M | 4.65M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | -91.00K | -108.30K | -105.84K | 0.00 | 0.00 | 0.00 |
| SG&A | 9.39M | 7.80M | 6.59M | 6.21M | 10.40M | 9.60M | 10.23M | 7.83M | 7.38M | 4.65M |
| Other Expenses | 0.00 | -113.00K | 105.00K | -150.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 14.41M | 16.16M | 12.81M | 10.16M | 51.77M | 52.82M | 30.52M | 24.13M | 22.29M | 11.60M |
| Cost & Expenses | 14.41M | 16.38M | 13.77M | 12.37M | 51.86M | 52.93M | 30.63M | 24.13M | 22.29M | 11.60M |
| Interest Income | 0.00 | 0.00 | 0.00 | 568.00K | 962.00K | 892.18K | 138.41K | 67.89K | 0.00 | 0.00 |
| Interest Expense | 1.00K | 10.00K | 64.00K | 0.00 | 696.00K | 662.40K | 70.00K | 70.00K | 70.00K | 462.57K |
| Depreciation & Amortization | 140.00K | 97.00K | 98.00K | 145.00K | 91.00K | 108.30K | 105.84K | 67.86K | -538.90K | 10.45K |
| EBITDA | -10.50M | -14.90M | -18.66M | -2.86M | -17.22M | -16.63M | -29.56M | -24.01M | -22.79M | -15.14M |
| EBITDA Ratio | -278.67% | -1,680.85% | -221.95% | 9.29% | -54.15% | -49.30% | -3,720.18% | 0.00% | 0.00% | 0.00% |
| Operating Income | -10.64M | -15.46M | -11.71M | 905.00K | -18.28M | -17.55M | -29.83M | -24.15M | -22.32M | -15.62M |
| Operating Income Ratio | -282.38% | -1,681.94% | -568.92% | 8.01% | -54.42% | -49.61% | -3,733.42% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -1.00K | 448.00K | -7.10M | -1.93M | 267.00K | 154.07K | 98.33K | -17.92K | 0.00 | -4.02M |
| Income Before Tax | -10.64M | -15.01M | -18.82M | -3.00M | -18.01M | -17.40M | -29.73M | -24.15M | -22.32M | -15.62M |
| Income Before Tax Ratio | -282.41% | -1,633.19% | -913.89% | -26.55% | -53.62% | -49.17% | -3,721.12% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -604.00K | 6.96M | 1.90M | 963.00K | 816.47K | 168.32K | 70.00K | 70.00K | 462.57K |
| Net Income | -10.62M | -14.41M | -25.77M | -4.90M | -18.01M | -17.40M | -29.73M | -24.15M | -22.32M | -15.62M |
| Net Income Ratio | -281.80% | -1,567.46% | -1,251.77% | -43.33% | -53.62% | -49.17% | -3,721.12% | 0.00% | 0.00% | 0.00% |
| EPS | -3.46 | -7.51 | -57.16 | -8.29 | -118.60 | -121.71 | -262.55 | -1.30 | -1.44 | -2.12 |
| EPS Diluted | -3.46 | -7.51 | -57.16 | -8.29 | -118.60 | -121.71 | -262.55 | -1.30 | -1.44 | -2.12 |
| Weighted Avg Shares Out | 3.21M | 1.92M | 450.92K | 590.69K | 151.85K | 142.93K | 113.25K | 18.62M | 15.48M | 7.36M |
| Weighted Avg Shares Out (Dil) | 3.21M | 1.92M | 450.92K | 590.69K | 151.85K | 142.93K | 113.25K | 18.62M | 15.48M | 7.36M |
Histogen Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Business Update
Strengthened Balance Sheet with $25.3 Million of Gross Proceeds from Financings and Warrant Exercises
Histogen Strengthens Board of Directors with Appointment of Industry Leader Susan Windham-Bannister, Ph.D.
SAN DIEGO, March 10, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function has appointed Susan R....
Histogen to Report Fourth Quarter and Year-End 2020 Financial Results and Provide Business Update
SAN DIEGO, March 04, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function, today announced that Histogen's...
Histogen Reports FDA Clinical Hold for Planned Phase 1/2 Trial of HST-003 for Knee Cartilage Regeneration
SAN DIEGO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function today announced that the...
Histogen Announces Closing of $14.0 Million Upsized Public Offering
SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (Nasdaq: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class therapeutics that ignite the body's natural process to repair and maintain healthy biological function, today announced that it has...
The Daily Biotech Pulse: CureVac Close To Coronavirus Vaccine Deal With EU, Entera Bio's Positive Readout, Patent Protection For Co-Diagnostics
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 19) 10X Genomics Inc (NASDAQ: TXG) ALX Oncology Holdings Inc (NASDAQ: ALXO) Avenue Therapeutics Inc (NASDAQ: ATXI)...
The Week Ahead In Biotech: Bausch Health, Fennec Pharma FDA Decisions And Smid-cap Earnings
Biotech stocks advanced in the week ended Aug. 7, buoyed by multiple catalysts. Aside from the broader market strength, mostly positive earnings and continuing coronavirus...
Source: https://incomestatements.info
Category: Stock Reports